• DOI:10.1016/j.pbb.2014.06.008
Corpus ID: 42990883

Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors

@article{Yoshimi2014EffectsOB,
  title={Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors},
  author={N. Yoshimi and Y. Fujita and Y. Ohgi and T. Futamura and K. Hashimoto},
  journal={Pharmacology Biochemistry and Behavior},
  year={2014},
  volume={124},
  pages={245-249}
}

N. Yoshimi, Y. Fujita, +2 authors K. Hashimoto

Published 2014

Psychology, Medicine

Pharmacology Biochemistry and Behavior

Brexpiprazole, a serotonin-dopamine activity modulator, is currently being tested in clinical trials as a new therapy for a number of neuropsychiatric diseases, including schizophrenia and major depressive disorder. Accumulating evidence suggests that 5-hydroxytryptamine (5-HT)1A receptors play a role in cognition. This study was undertaken to examine whether brexpiprazole, a novel drug with 5-HT1A receptor partial agonism, could improve cognitive deficits in mice, induced by repeated… CONTINUE READING

View on Elsevier

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed